Jointly Provided by The University of Texas Southwestern Medical Center and Medical Logix, LLC
This activity is supported by educational grants from EMD Serono and Sanofi Genzyme.
Highly active multiple sclerosis (MS) is a chronic, inflammatory and degenerative disorder that results in rapid and profound accrual of neurological disability. The 2018 AAN Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis now suggests that specific agents be offered to individuals with highly active MS. Clinicians must have a thorough understanding of the efficacy and safety profiles of these therapies and be able to make recommendations based on a patient’s preferences and risk tolerance. In addition, ongoing surveillance for medication adherence, adverse events, relapses, and disability accumulation is essential.
This activity is intended for healthcare professionals, specifically, neurologists, internists, family practice physicians, nurse practitioners, physician assistants, nurses and other providers involved in the care of patients with multiple sclerosis.
After completing this activity, the participant should be better able to:
Identify the characteristics of highly active MS and apply this knowledge to assessing MS severity in patients.
Describe the induction treatment approach and rationale for its use in highly active MS patients.
Explain the American Academy of Neurology (AAN) recommendations for therapies and other commonly utilized treatments in highly active MS.
Cite the potential serious adverse effects associated with drugs used in treating highly active MS and be familiar with the laboratory monitoring practices for these therapies.
Identify when MS patients are not sufficiently responding to a disease-modifying therapy (DMT) and consider options for switching therapies.
Recognize when a highly active MS patient has progressed to secondary progressive MS and may no longer benefit from treatments targeted at relapsing disease.
Conflict Of Interest Disclosure Policy
All individuals who affect the content of continuing education activities are required to disclose to the audience any real or apparent conflict of interest related to the activity. The activity faculty are further required to disclose discussion of off-label/investigational uses in their presentations. The following relationships have been reported for this activity:
Moderator Benjamin M. Greenberg, MD, MHS Vice Chair of Translational Research and Strategic Initiatives Cain Denius Scholar of Mobility Disorders Distinguished Teaching Professor Department of Neurology and Neurotherapeutics Department of Pediatrics UT Southwestern Medical Center Dallas, Texas
Dr. Greenberg discloses the following: Consultant: Alexion, EMD Serono, Novartis Research Activities: Chugai, Medday, Medimmune
Joseph R. Berger, MD, FACP, FAAN, FANA Professor of Neurology and Associate Chief of MS Division Department of Neurology Perelman School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania
Dr. Berger discloses the following: Consultant: Amgen, Biogen, Genentech/Roche, Genzyme, Millennium/Takeda, Novartis Research Activities: Biogen Formal Advisor: Excision Bio, Inhibikase
Olaf Stuve, MD, PhD Professor Department of Neurology and Neurotherapeutics UT Southwestern Medical Center Dallas, Texas
Chief Neurology Section VA North Texas Health Care System, Medical Service Dallas VA Medical Center Dallas, Texas
Dr. Stuve discloses the following: Consultant: EMD Serono, Merck, Sanofi/Genzyme Research Activities: Sanofi/Genzyme
Reviewer: Cynthia Wang, MD Assistant Professor Pediatrics Neurology and Neurotherapeutics UT Southwestern Medical Center Dallas, TX
Dr. Wang has no relevant financial relationships to disclose.
Accredited Provider Disclosure
The following UT Southwestern employee, Ericka Harden-Dews, JD, CHCP, has no relationship with any commercial interests whose products or services may be mentioned during this presentation.
Publishing Staff Disclosures
Michael Speidel and John Gentile, Medical Logix, LLC and Nancy Baxter, Baxter Medical Communications, have no relationship with any commercial interests whose products or services may be mentioned during this presentation.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The University of Texas Southwestern Medical Center and Medical Logix LLC. The University of Texas Southwestern Medical Center is accredited by the ACCME to provide continuing medical education for physicians.
The University of Texas Southwestern Medical Center designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Participants should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Nurse Practitioner and Physician Assistant Credit Reciprocity:
American Association of Nurse Practitioners (AANP) National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the ACCME. Physician Assistants may receive a maximum of 1.50 credits of Category 1 for completing this program.
Disclosure of Unlabeled Use
Olaf Stuve, MD, PhD – Azathioprine, methotrexate, cyclophosphamide
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.